Diabetes Dialogue: SELECT Proves Semaglutide 2.4 mg CV Benef

In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.

Related Keywords

United States , American , Natalie Bellini , Diana Isaacs , Pa Michael Lincoff , Metabolic Care Center , Diabetes Technology At University Hospitals , Suzanne Tomsich Department Of Cardiovascular Medicine , American Heart Association , Training In Diabetes Technology , Drug Administration , American Heart Association Scientific Sessions , Vascular Thoracic Institute , Suzanne Tomsich Department , Cardiovascular Medicine , Arnold Miller Family Heart , Thoracic Institute , Diabetes Technology , Endocrine Disorders , Cleveland Clinic , University Hospitals Diabetes , Diabetes Dialogue , Cardiovascular Outcomes , New England Journal , Accessed November , Select Trial , Semaglutide 2 4 Mg Wegovy ,